Neuland Laboratories Reports Strong Financial Performance in Q1 FY25, with Positive Trends in Key Areas

Aug 01 2024 05:18 PM IST
share
Share Via
Neuland Laboratories, a midcap pharmaceutical company, has reported a positive financial performance in the quarter ending June 2024. The company's operating cash flow, PAT, net sales, and EPS have shown consistent growth, indicating a strong demand for its products. However, the DPR is at its lowest in five years.

Neuland Laboratories, a midcap pharmaceutical company, has recently announced its financial results for the quarter ending June 2024. The company has shown a positive performance in this quarter, with its score improving from 7 to 9 in the last 3 months according to MarketsMOJO.

One of the key factors contributing to this positive performance is the company’s strong operating cash flow. Neuland Labs. has recorded the highest annual operating cash flow of Rs 261.18 crore and has shown consistent growth in the last three years. This indicates that the company has been able to generate higher revenues from its business operations.


Another highlight of the financial results is the company’s Profit After Tax (PAT) for the nine-month period, which stands at Rs 231.27 crore, showing a growth of 30.68% year on year. This indicates a positive trend in the company’s profitability in the near term.


Neuland Labs. has also shown a positive trend in its net sales for the quarter, with the highest recorded sales of Rs 439.60 crore in the last five quarters. This indicates a strong demand for the company’s products in the market.


The company’s Earnings per Share (EPS) for the quarter also saw a significant increase, reaching its highest at Rs 75.87 in the last five quarters. This shows that the company has been able to create higher earnings for its shareholders, indicating a positive outlook for the company’s future.


However, one area of concern for Neuland Labs. is its Dividend Payout Ratio (DPR), which is at its lowest at 6.02% in the last five years. This indicates that the company is distributing a lower proportion of its profits as dividends to its shareholders.


Overall, Neuland Laboratories has shown a strong financial performance in the quarter ending June 2024, with positive trends in key areas such as operating cash flow, PAT, net sales, and EPS. Investors can take note of the company’s positive performance and consider the stock as a ‘Buy’ option, as suggested by MarketsMOJO.


{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News